Patient pathways for four major chronic respiratory diseases in England between 2008 and 2021

Abstract

BackgroundNot all chronic diseases have clear pathways and time targets for diagnosis. We explored pathways and timings for four major chronic respiratory diseases in England.MethodsUsing deidentified electronic healthcare records from Clinical Practice Research Datalink Aurum linked to Hospital Episode Statistics, we derived cohorts of patients diagnosed with asthma, chronic obstructive pulmonary disease (COPD), ILD or bronchiectasis at three time periods (2008/2009, 2018/2019 and 2020/2021). We followed people 2 years before and 2 years after diagnosis, calculating the proportion of people who presented with symptoms, underwent diagnostic tests, were treated and consulted healthcare (primary or secondary) and calculated time intervals between events. We repeated analyses by socioeconomic status and geographical region.ResultsWe descriptively studied patient pathways for 429 619 individuals across all time frames and diseases. Most people (>87%) had first evidence of diagnosis in primary care. The proportion of people reporting symptoms prior to diagnosis was similar for asthma, COPD and ILD (41.0%–57.9%) and higher in bronchiectasis (67.9%–71.8%). The proportion undergoing diagnostic tests was high for COPD and bronchiectasis (77.6%–89.2%) and lower for asthma (14%–32.7%) and ILD (2.6%–3.3%). The proportion of people undergoing diagnostic tests decreased in 2020/2021 for all diseases, mostly COPD. Time (months) (median (IQR)) between symptoms and diagnosis, averaged over three time periods, was lowest in asthma (~7.5 (1.3–16.0)), followed by COPD (~8.6 (1.8–17.2)), ILD (~10.1 (3.6–18.0)) and bronchiectasis (~13.5 (5.9–19.8)). Time from symptoms to diagnosis increased by ~2 months in asthma and COPD over the three time periods. Although most patients were symptomatically treated prior to diagnosis, time between diagnosis and postdiagnostic treatment was around 4 months for ILD, 3 months for bronchiectasis and instantaneous for asthma and COPD. Socioeconomic status and regional trends showed little disparity.ConclusionCurrent pathways demonstrate missed opportunities to diagnose and manage disease and to improve disease coding.